BNP Paribas Financial Markets’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-98
| Closed | -$396 | – | 5474 |
|
|
2025
Q1 | $396 | Hold |
98
| – | – | ﹤0.01% | 5159 |
|
|
2024
Q4 | $314 | Buy |
+98
| New | +$332 | ﹤0.01% | 5210 |
|
|
2022
Q4 | – | Sell |
-98
| Closed | -$1.02K | – | 4154 |
|
|
2022
Q3 | $1.02K | Hold |
98
| – | – | ﹤0.01% | 4426 |
|
|
2022
Q2 | $1.01K | Hold |
98
| – | – | ﹤0.01% | 3907 |
|
|
2022
Q1 | $1.74K | Sell |
98
-46
| -32% | -$988 | ﹤0.01% | 3919 |
|
|
2021
Q4 | $4.49K | Sell |
144
-9
| -6% | -$298 | ﹤0.01% | 3940 |
|
|
2021
Q3 | $5.03K | Sell |
153
-28
| -15% | -$828 | ﹤0.01% | 3711 |
|
|
2021
Q2 | $5.33K | Sell |
181
-481
| -73% | -$13.3K | ﹤0.01% | 3798 |
|
|
2021
Q1 | $20.8K | Sell |
662
-442
| -40% | -$14.8K | ﹤0.01% | 3751 |
|
|
2020
Q4 | $29.3K | Sell |
1,104
-717
| -39% | -$18.1K | ﹤0.01% | 3762 |
|
|
2020
Q3 | $48.8K | Buy |
1,821
+885
| +95% | +$21.3K | ﹤0.01% | 3475 |
|
|
2020
Q2 | $18.5K | Buy |
936
+67
| +8% | +$1.22K | ﹤0.01% | 3429 |
|
|
2020
Q1 | $13.1K | Buy |
869
+557
| +179% | +$9.86K | ﹤0.01% | 3992 |
|
|
2019
Q4 | $5.36K | Buy |
312
+200
| +179% | +$3.35K | ﹤0.01% | 4184 |
|
|
2019
Q3 | $2.79K | Buy |
112
+106
| +1,767% | +$2.91K | ﹤0.01% | 4336 |
|
|
2019
Q2 | $179 | Buy |
+6
| New | +$235 | ﹤0.01% | 4460 |
|
BNP Paribas Financial Markets's CKPT Position: Q2 2025 in Review
BNP Paribas Financial Markets sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 98 shares — an estimated $396 sold.
BNP Paribas Financial Markets first reported a position in CKPT in Q2 2019 and held it in 16 quarters. The position peaked at $48.8K in Q3 2020. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- BNP Paribas Financial Markets reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- BNP Paribas Financial Markets sold 98 Checkpoint Therapeutics shares in Q2 2025, an estimated $396.
- BNP Paribas Financial Markets first reported a position in Checkpoint Therapeutics in Q2 2019 and held it in 16 quarters.
- BNP Paribas Financial Markets's Checkpoint Therapeutics position peaked at $48.8K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2025, filed 14 Aug 2025.